Use of isogenic human cancer cells for high-throughput screening and drug discovery
- 1 October 2001
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 19 (10), 940-945
- https://doi.org/10.1038/nbt1001-940
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeThe New England Journal of Medicine, 2001
- Transgenic gene knock-outs: functional genomics and therapeutic target selectionPharmacogenomics, 2000
- Understanding Ras: ‘it ain’t over ’til it’s over’Trends in Cell Biology, 2000
- Green fluorescent protein (GFP): applications in cell-based assays for drug discoveryDrug Discovery Today, 1999
- Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein KinaseJournal of Medicinal Chemistry, 1999
- Gene Targeting in Human Cells Without Isogenic DNAScience, 1999
- SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1FEBS Letters, 1995
- The G-C Specific DNA Binding Drug, Mithramycin, Selectively Inhibits Transcription of the C-MYC and C-HA-RAS Genes in Regenerating LiverThe American Journal of the Medical Sciences, 1994
- Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki- rasScience, 1993
- 2, 3, 5-triphenyl tetrazolium chloride (TTC) reduction as exponential growth phase marker for mammalian cells in culture and for myeloma hybridization experimentsCytotechnology, 1991